Mativ Holdings, Inc. · NYSE:MATV
Mativ — Q1 2025 Earnings Presentation
11 slides from Mativ's earnings presentation, May 8, 2025
Slide 1: Mativ First Quarter 2025 Earnings Release Presentation
Mativ First Quarter 2025 Earnings Release Presentation May 2025
Slide 2: Forward Looking Statements, Non-GAAP Disclosure, & Definitions
Forward Looking Statements, Non-GAAP Disclosure, & Definitions This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws that are subject to the safe harbor created by such laws and other le
Slide 3: Q1 Consolidated Results
Q1 Consolidated Results • Sales essentially flat organically year-over-year ($ millions, except EPS) Q1 FY25 Q1 FY24 Sales $484.8 $500.2 • Volume improvements in SAS were largely offset by continued lower Organic Sales $484.8 $483.9 demand across many of our FAM product categories % versus: +0% • GA
Slide 4: Q1 Consolidated Results Variances
Q1 Consolidated Results Variances Net Sales Adj. EBITDA $500.2 $45.8 $1.1 $(1.3) $(11.7) $484.8 $(2.5) $(4.7) $37.2 $(4.8) Q1 FY24 Volume/Mix Price Currency Q1 FY25 Volume/Mix Mfg. Costs & Q1 FY24 Price/Cost Other Q1 FY25 Note: Adjusted EBITDA is a non-GAAP measure and reconciled in the appendix of
Slide 5: Q1 Segment Results
Q1 Segment Results ($ millions) Q1 FY25 Q1 FY24 • FAM Sales reflecting lower volume/mix, lower selling prices and Sales $187.6 $202.7 unfavorable currency translation % versus: -7% • SAS Sales were up 6% on organic basis as higher volume across all FAM GAAP Operating Profit $(410.0) $14.6 product ca
Slide 6: 2025 Key Priorities To Drive Improved Performance
2025 Key Priorities To Drive Improved Performance Driving De-Lever through Margin and Cash Conduct Enhanced Commercial Execution Flow Improvement Strategic Portfolio Review • Leverage successful SAS go-to-market • Announced pricing actions effective in • Strategic review of assets and business lines
Slide 7: 2025 Full Year Considerations
2025 Full Year Considerations • Additional cost reductions of $10-15 million • Depreciation, amortization and stock-based comp to be around $100 million • Interest expense to be around $75 million plus another $9 million in fees for our A/R facility • Capital expenditures of around $40 million • One
Slide 8: Appendix
Appendix ANNSAANS AANANAANS AANANAN TVS
Slide 9: Non-GAAP Reconciliation: Segment Reporting
Non-GAAP Reconciliation: Segment Reporting 9
Slide 10: Non-GAAP Reconciliation: Segment Reporting (cont.)
Non-GAAP Reconciliation: Segment Reporting (cont.) 10
Slide 11: Non-GAAP Reconciliation: Consolidated Reported Results
Non-GAAP Reconciliation: Consolidated Reported Results 11